Sucrosomial® Iron Effectiveness in Recovering from Mild and Moderate Iron-deficiency Anemia in the Postpartum Period

Overview

Journal BMC Pregnancy Childbirth

Publisher Biomed Central

Specialty Gynecology & Obstetrics

Date 2023 May 17

PMID 37198549

Authors

Edu Antoine

Claudia Mehedintu

Mihai Mitran

Doru Diculescu

Affiliations

Soon will be listed here.

Abstract

Background: Postpartum iron deficiency anemia (PPIDA) is highly prevalent in developing countries where it constitutes an important cause of maternal morbidity and mortality. Potential determinants of PPIDA are prepartum iron deficiency or iron deficiency anemia in association with severe blood loss during delivery. We investigated the efficacy of oral Sucrosomial® iron for recover from mild-to-moderate PPIDA.

Methods: This pilot study was conducted in three medical centers in Romania. Adult women (≥ 18y) with mild (hemoglobin [Hb] 9-11 g/dL) or moderate (Hb 7-9 g/dL) PPIDA diagnosed at screening (2-24 h after delivery) were eligible. Women with mild PPIDA received oral Sucrosomial® iron (Pharmanutra, S.p.A, Italy) once daily (30 mg elemental iron per capsule) for 60 days. Those with moderate PPIDA received oral Sucrosomial® iron twice daily (60 mg elemental iron) for 10 days, followed by a 50-day course of oral Sucrosomial® iron once daily (30 mg elemental iron). Laboratory parameters, as well as subjective clinical symptoms using a 3-point Likert Scale, were assessed at baseline and on study days 10, 30 and 60.

Results: Sixty anemic women entered the study, but three were missed during follow-up. At day 60, a Hb rise was observed in both groups (+ 3.6 ± 1.5 g/dL; p < 0.01), 81% experienced correction of anemia (Hb ≥ 12 g/dL), 36% achieved a ferritin concentration ≥ 30 ng/mL (p < 0.05), and 54% a transferrin saturation (TSAT) ≥ 20% (p < 0.01). For women still anemic at day 60, mean Hb was close to normality (11.3 ± 0.8 g/dL). Resolution of IDA-associated clinical symptoms was already observed just 10 days after treatment initiation. No patient discontinued treatment due to gastrointestinal adverse events.

Conclusions: Sucrosomial® iron was shown to be potentially effective and well tolerated at treating mild and moderate PPIDA. These results encourage the use of oral Sucrosomial® iron as a treatment option for PPIDA, but larger studies with longer follow-up are warrant.

Citing Articles

Management of postpartum anemia.

Holm C, Neef V, Pavord S Blood Transfus. 2025; 23(1):47-49.

PMID: 39804748 PMC: 11841944. DOI: 10.2450/BloodTransfus.924.

Oral iron supplementation: new formulations, old questions.

Pantopoulos K Haematologica. 2024; 109(9):2790-2801.

PMID: 38618666 PMC: 11367235. DOI: 10.3324/haematol.2024.284967.

Sucrosomial Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency.

Gomez-Ramirez S, Brilli E, Tarantino G, Girelli D, Munoz M Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375794 PMC: 10305423. DOI: 10.3390/ph16060847.

References

Van Wyck D, Martens M, Seid M, Baker J, Mangione A . Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007; 110(2 Pt 1):267-78. DOI: 10.1097/01.AOG.0000275286.03283.18. View

Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J . UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2019; 188(6):819-830. DOI: 10.1111/bjh.16221. View

Munoz M, Stensballe J, Ducloy-Bouthors A, Bonnet M, De Robertis E, Fornet I . Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. Blood Transfus. 2019; 17(2):112-136. PMC: 6476742. DOI: 10.2450/2019.0245-18. View

Karavidas A, Troganis E, Lazaros G, Balta D, Karavidas I, Polyzogopoulou E . Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study. Eur J Heart Fail. 2021; 23(4):593-597. DOI: 10.1002/ejhf.2092. View

Pena-Rosas J, De-Regil L, Garcia-Casal M, Dowswell T . Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015; (7):CD004736. PMC: 8918165. DOI: 10.1002/14651858.CD004736.pub5. View

Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B . Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2014; 30(4):645-52. DOI: 10.1093/ndt/gfu357. View

Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M . Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017; 25(9):2779-2786. PMC: 5527057. DOI: 10.1007/s00520-017-3690-z. View

Seid M, Derman R, Baker J, Banach W, Goldberg C, Rogers R . Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008; 199(4):435.e1-7. DOI: 10.1016/j.ajog.2008.07.046. View

Gredilla E, Gimeno M, Canser E, Martinez B, Perez Ferrer A, Gilsanz F . [Postpartum and early postoperative anemia after gynecological surgery: treatment with intravenous iron]. Rev Esp Anestesiol Reanim. 2006; 53(4):208-13. View

10.

Elli L, Ferretti F, Branchi F, Tomba C, Lombardo V, Scricciolo A . Sucrosomial Iron Supplementation in Anemic Patients with Celiac Disease Not Tolerating Oral Ferrous Sulfate: A Prospective Study. Nutrients. 2018; 10(3). PMC: 5872748. DOI: 10.3390/nu10030330. View

11.

Munoz M, Gomez-Ramirez S, Besser M, Pavia J, Gomollon F, Liumbruno G . Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus. 2017; 15(5):422-437. PMC: 5589705. DOI: 10.2450/2017.0113-17. View

12.

Camaschella C . Iron-deficiency anemia. N Engl J Med. 2015; 372(19):1832-43. DOI: 10.1056/NEJMra1401038. View

13.

Milman N . Postpartum anemia I: definition, prevalence, causes, and consequences. Ann Hematol. 2011; 90(11):1247-53. DOI: 10.1007/s00277-011-1279-z. View

14.

Abbati G, Incerti F, Boarini C, Pileri F, Bocchi D, Ventura P . Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia. Intern Emerg Med. 2018; 14(3):423-431. DOI: 10.1007/s11739-018-1993-9. View

15.

Munoz M, Pena-Rosas J, Robinson S, Milman N, Holzgreve W, Breymann C . Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. Transfus Med. 2017; 28(1):22-39. DOI: 10.1111/tme.12443. View

16.

Milman N . Postpartum anemia II: prevention and treatment. Ann Hematol. 2011; 91(2):143-54. DOI: 10.1007/s00277-011-1381-2. View

17.

Bergmann R, Richter R, Bergmann K, Dudenhausen J . Prevalence and risk factors for early postpartum anemia. Eur J Obstet Gynecol Reprod Biol. 2010; 150(2):126-31. DOI: 10.1016/j.ejogrb.2010.02.030. View

18.

Venturini E, Iannuzzo G, Di Lorenzo A, Cuomo G, DAngelo A, Merone P . Short-term treatment of iron deficiency anemia after cardiac surgery. Int J Cardiol Heart Vasc. 2022; 40:101038. PMC: 9066354. DOI: 10.1016/j.ijcha.2022.101038. View

19.

Breymann C, Gliga F, Bejenariu C, Strizhova N . Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008; 101(1):67-73. DOI: 10.1016/j.ijgo.2007.10.009. View

20.

Breymann C, Richter C, Huttner C, Huch R, Huch A . Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis. Eur J Clin Invest. 2000; 30(2):154-61. DOI: 10.1046/j.1365-2362.2000.00605.x. View